 | | Vol. 15.10 – 5 April, 2024 |
| |
|
|
| The authors examined the chromatin landscape of androgen receptor (AR)-positive prostate cancer cells post-exposure to the AR inhibitor enzalutamide.
[Nucleic Acids Research] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers confirmed that NURR1 exhibited an upregulation in prostate cancer and also enhanced expression in prostate cancer cell lines.
[Cell Death & Disease] |
|
|
|
| Investigators discovered a small molecule, SC912, which bound to to full-length androgen receptor (AR) as well as AR-V7 through AR N-terminal domain (AR-NTD). This pan-AR targeting relied on the amino acids 507–531 in the AR-NTD.
[Oncogene] |
|
|
|
| Scientists confirmed that lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was induced by non-SMC condensin II complex subunit D3 (NCAPD3)-STAT3, and the expression of miR-30a-5p was controlled by NCAPD3 in prostate cancer cells by miRNA-seq.
[Cell Death Discovery] |
|
|
|
| Researchers characterized FOXA1 alterations with respect to its regulation of semaphorin 3C (SEMA3C). They revealed that FOXA1 alterations led to elevated levels of SEMA3C both in prostate cancer specimens and in vitro.
[Scientific Reports] |
|
|
|
| Prostate cancer (PCa) cells from LNCaP and C4-2 cell lines, which had high prostate-specific membrane antigen (PSMA) and androgen receptor (AR) expression among PCa cell lines, were used in this study.
[The Prostate] |
|
|
|
|
| The authors delineate the mechanisms by which tumor-associated macrophages, cancer-associated fibroblasts, and myeloid-derived suppressor cells interact with prostate cancer cells in the tumor microenvironment.
[Prostate Cancer and Prostatic Diseases] |
|
|
|
| Investigators provide a comprehensive overview of current clinical opportunities in managing prostate cancer through blood-based liquid biopsy, highlighting the progress made, and acknowledging the challenges that remain.
[International Journal of Urology] |
|
|
|
|
| Convergent Therapeutics Inc. announced that the US FDA has cleared the investigational new drug (IND) application for CONV01-α, its lead candidate for the treatment of patients with advanced prostate cancer.
[Convergent Therapeutics Inc. (PR Newswire)] |
|
|
|
|
| April 17 – 19, 2024
London, England, United Kingdom |
|
|
|
|
|
| | Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| | KU Leuven – Leuven, Belgium |
|
|
|
| | Vall d’Hebron University Hospital – Barcelona, Spain |
|
|
|
| | Princess Margaret Cancer Centre – Toronto, Ontario, Canada |
|
|
|
| | Indiana University School of Medicine – Indianapolis, Indiana, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
